.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Evolving Treatment Landscape in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: DLBCL: Circumstances for Deviating Away From R-CHOP

January 29th 2021

EP. 2: DLBCL: Treatment Considerations for Challenging Populations

January 29th 2021

EP. 3: DLBCL: Treating Patients Following Relapse on Frontline Therapy

February 5th 2021

EP. 4: R/R DLBCL: Second-Line Treatment Options

February 5th 2021

EP. 5: Tafasitamab Combined With Lenalidomide in R/R DLBCL

February 12th 2021

EP. 6: R/R DLBCL: Treating With Tafasitamab-Lenalidomide

February 12th 2021

EP. 7: Novel Therapies for R/R DLBCL

February 19th 2021

EP. 8: CAR T-Cell Therapy for R/R DLBCL

February 19th 2021

EP. 9: CAR-T Treatment Options for R/R DLBCL

February 26th 2021

EP. 10: Treating R/R DLBCL With CAR-T: Current Barriers

February 26th 2021

EP. 11: Understanding the CAR-T Process: Collection Through Infusion

March 5th 2021

EP. 12: CAR T for R/R DLBCL: Safety/Tolerability

March 5th 2021

EP. 13: CAR T for R/R DLBCL: Improving Access and Utilization

March 12th 2021

EP. 14: R/R DLBCL: Transplants in the Era of CAR-T

March 12th 2021

EP. 15: Bridging Therapy in R/R DLBCL

March 19th 2021

EP. 16: Treating Primary Refractory DLBCL

March 19th 2021

EP. 17: R/R DLBCL: Novel Therapies in the Pipeline

March 26th 2021

EP. 18: R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

March 26th 2021

EP. 19: Evolving Therapies in R/R DLBCL: Concluding Remarks

March 26th 2021